Amicus Therapeutics - FOLD Stock Forecast, Price & News

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded up $0.05 during trading hours on Monday, reaching $12.37. 1,260,680 shares of the company were exchanged, compared to its average volume of 3,468,885. The company has a current ratio of 3.02, a quick ratio of 2.90 and a debt-to-equity ratio of 2.25. The stock's 50-day moving average is $10.41 and its 200-day moving average is $9.12. The firm has a market cap of $3.47 billion, a PE ratio of -12.44 and a beta of 0.96. Amicus Therapeutics has a twelve month low of $5.91 and a twelve month high of $12.76.

Amicus Therapeutics (NASDAQ:FOLD - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative return on equity of 102.55%. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. On average, sell-side analysts anticipate that Amicus Therapeutics will post -0.9 earnings per share for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 5,470 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.03, for a total transaction of $54,864.10. Following the completion of the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at $6,916,868.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Bradley L. Campbell sold 5,470 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.03, for a total transaction of $54,864.10. Following the completion of the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at $6,916,868.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John F. Crowley sold 11,346 shares of the company's stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the completion of the sale, the chief executive officer now directly owns 932,807 shares of the company's stock, valued at approximately $7,462,456. The disclosure for this sale can be found here. Insiders sold 130,779 shares of company stock valued at $1,237,966 over the last 90 days. 2.10% of the stock is currently owned by corporate insiders.